Matthew Grosso, MD
The primary purpose of this study is to evaluate postoperative pain. Secondary outcomes evaluated in this study will include range of motion (ROM), opioid consumption, and ambulation. Each outcome measure will be evaluated, oral tranexamic acid (TXA) in the experiment arm and placebo in the control arm, after total knee arthroplasty (TKA) at postoperative days 0-3, and weeks 1, 2, 6, and 12.
Randomized controlled trial with 1:1 allocation, selected through computer-based randomization. This study will review prospectively collected data, including patient demographic information, surgeon, use of oral tranexamic acid (TXA) or placebo regimen, and postoperative outcomes up to 3 months after surgery. Collaboration with Saint Francis' pharmacy team will be performed to ensure appropriate blinded administering of the oral TXA and placebo medication. This will be a double blinded study, with both patient and surgeon blinded to study group. 6.0 TXA dosing protocol TXA day of surgery \…
Inclusion Criteria: * \- All patients undergoing either manual or robotic primary total knee arthroplasty (TKA) * Performed by participating Connecticut Joint Replacement Institute (CJRI) surgeons (Dr. Matthew Grosso, Dr. Robert McAllister, Dr. Chad Daniel, Dr. Eric Silverstein, Dr. Alex Dukas, Dr. Michael Joyce, Dr. Brett Wasserlauf). * Male and female patient age 18-89 * Primary diagnosis of knee osteoarthritis Exclusion Criteria: * Revision TKA * No exclusion based on gender * Patients \<18 and \>89 years old * Exclusion for IV oral tranexamic acid (TXA): * TXA allergy - there are NO…
1.95 grams oral
Arctuva estimate
Verify or correct the compensation shown for this listing.